| Signifor LAR (pasireotide long acting release) / Recordati |
NCT00929669: Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas |
|
|
| Terminated | 2 | 2 | US | pasireotide LAR, SOM230 | University of Pennsylvania | Gonadotroph Adenomas | 11/11 | 11/11 | | |
NCT00859040: Monthly SOM230C for Recurrent or Progressive Meningioma |
|
|
| Completed | 2 | 34 | US | SOM230C, pasireotide LAR | Patrick Y. Wen, MD, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center, Wake Forest University Health Sciences, Duke University, Cedars-Sinai Medical Center, Northwestern University, Novartis | Meningioma | 12/11 | 01/16 | | |
NCT01329289: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma |
|
|
| Withdrawn | 2 | 0 | US | SOM230, Pasireotide, Bortezomib, Velcade, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, dexamethasone sodium phosphate, dexamethasone acetate | University of Pittsburgh, Novartis | Multiple Myeloma in Relapse, Multiple Myeloma | 02/12 | 02/12 | | |
NCT01234974: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus |
|
|
| Withdrawn | 2 | 0 | US | Pasireotide, Pasireotide s.c., Pasireotide LAR, SOM230, Everolimus, RAD001 | Milton S. Hershey Medical Center | Multiple Myeloma | 12/12 | 12/13 | | |
NCT01488487: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma |
|
|
| Completed | 2 | 24 | US | Everolimus, Afinitor, RAD001, Pasireotide, SOM230, Pasireotide LAR, Pasireotide s.c. | UNC Lineberger Comprehensive Cancer Center, Novartis Pharmaceuticals | Advanced Adult Hepatocellular Carcinoma | 03/15 | 03/15 | | |
NCT02021942 / 2010-019017-25: Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size |
|
|
| Completed | 2 | 16 | Europe | SOM230 LAR, Pasireotide, Sandostatin® | Prof. Dr. Berthold Schalke, Crolll Gmbh | Primary Inoperable Thymoma, Local Recurrent Thymoma | 10/15 | 10/15 | | |
NCT01639352: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 2 | 20 | US | SOM230, Pasireotide LAR, SOM230C | Lynn Feun | Hepatocellular Carcinoma | 08/16 | 02/17 | | |
Passion I, NCT01283542: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. |
|
|
| Completed | 2 | 20 | RoW | Pasireotide LAR | Novartis Pharmaceuticals | Non-functioning Pituitary Adenoma | 09/17 | 09/17 | | |
